Diastolic dysfunction is a feature of the antiphospholipid syndrome

Hasnie, Abdul M.A.; Stoddard, Marcus F.; Gleason, Carolyn B.; Wagner, Stephen; Longaker, Rita A.; Pierangeli, Silvia S.; Harris, E. N.

doi:10.1016/0002-8703(95)90124-8

Cited by 39 publications

(23 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Subclinical LV diastolic dysfunction usually preceded systolic dysfunction in previous studies of PAPS patients [36,37] or SLE [34,35] patients and has been associated with longer SLE duration [34] or disease activity [35]. In the same line of evidence, our data suggest that left ventricular diastolic function worsens in PAPS and all SLE groups over time, despite the stable and normal LV systolic function.…”

Section: Discussionsupporting

confidence: 81%

“…Diastolic dysfunction has also been observed by our group and others in patients with APS and SLE [17,18,[34][35][36][37]. However, only few studies prospectively examined the outcome of valve disease or diastolic dysfunction in these patients [3,[9][10][11][13][14][15][16]19], most of them in a short follow-up period (r 5 years) [3,9,10,[13][14][15][16] and either only in APS [13,14,19] or only in SLE patients (with or without aPL) [3,[9][10][11]15,16] (Supplementary Table 2).…”

Section: Discussionmentioning

confidence: 63%

See 1 more Smart Citation

Evolution of cardiac dysfunction in patients with antiphospholipid antibodies and/or antiphospholipid syndrome: A 10-year follow-up study

Kampolis¹,

Tektonidou²,

Moyssakis³

et al. 2014

Seminars in Arthritis and Rheumatism

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 81%

Section: Discussionmentioning

confidence: 63%

Evolution of cardiac dysfunction in patients with antiphospholipid antibodies and/or antiphospholipid syndrome: A 10-year follow-up study

Kampolis¹,

Tektonidou²,

Moyssakis³

et al. 2014

Seminars in Arthritis and Rheumatism

View full text Add to dashboard Cite

“…These manifestations are frequently associated with cardiac abnormalities [3, 4, 17, 18]. However, in our study none of the patients suffered from amyloidosis, and although 25% of the patients (n = 6) from the SLE subgroup had detectable low-to-moderate anticardiolipin IgG levels, none of them had valvular lesions, pericardial effusion, or a clinically proven APS.…”

Section: Discussioncontrasting

confidence: 53%

Atrial Ejection Force in Systemic Autoimmune Diseases

1999

View full text Add to dashboard Cite

Systemic autoimmune disorders may affect several organs, including the heart. We analyzed two-dimensional and pulsed Doppler echocardiograms of patients (n = 37) with systemic lupus erythematosus (SLE, n = 24) or rheumatoid arthritis (RA, n = 13) to determine whether atrial ejection force (AEF) could represent a suitable parameter for detecting left ventricular filling abnormalities in SLE and RA. In both patient subgroups, AEF was significantly higher than in healthy controls (n = 40) matched for gender and age (14.0 ± 5.4 vs. 11.0 ± 3.5 kdyn, p < 0.01). Because conventional echocardiographic parameters of left ventricular function failed to detect such a difference, AEF might serve as an additional sensitive parameter for detecting left ventricular diastolic filling abnormalities early in the course of a systemic autoimmune disease.

show abstract

“…However, chronic cardiomyopathy may be global or localized, whereas a segmental ventricular dysfunction can supervene 27. Impaired left ventricular diastolic filling was also observed28 and associated with cardiomyopathy or myocardial ischaemia (the latter provoked by coronary arteriolar occlusions). Both may lead to myocardial fibrosis and a decrease in left ventricular compliance.…”

Section: Aps and Vaso-ischemic (Occlusive) Diseases With Neuropsychiamentioning

confidence: 99%

Antiphospholipid Syndrome and Vascular Ischemic (Occlusive) Diseases: An Overview

Atanassova

2007

Yonsei Med J

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) is primarily considered to be an autoimmune pathological condition that is also referred to as "Hughes syndrome". It is characterized by arterial and/or venous thrombosis and pregnancy pathologies in the presence of anticardiolipin antibodies and/or lupus anticoagulant. APS can occur either as a primary disease or secondary to a connective tissue disorder, most frequently systemic lupus erythematosus (SLE). Damage to the nervous system is one of the most prominent clinical constellations of sequelae in APS and includes (i) arterial/venous thrombotic events, (ii) psychiatric features and (iii) other non-thrombotic neurological syndromes. In this overview we compare the most important vascular ischemic (occlusive) disturbances (VIOD) with neuro-psychiatric symptomatics, together with complete, updated classifications and hypotheses for the etio-pathogenesis of APS with underlying clinical and laboratory criteria for optimal diagnosis and disease management.

show abstract

Diastolic dysfunction is a feature of the antiphospholipid syndrome

Cited by 39 publications

References 34 publications

Evolution of cardiac dysfunction in patients with antiphospholipid antibodies and/or antiphospholipid syndrome: A 10-year follow-up study

Evolution of cardiac dysfunction in patients with antiphospholipid antibodies and/or antiphospholipid syndrome: A 10-year follow-up study

Atrial Ejection Force in Systemic Autoimmune Diseases

Antiphospholipid Syndrome and Vascular Ischemic (Occlusive) Diseases: An Overview

Contact Info

Product

Resources

About